This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Glioblastoma Treatment Drugs Market

Government’s Initiatives Plans Strengthening Healthcare Sector in the Glioblastoma Treatment Drugs. Explore More Trends

Glioblastoma Treatment Drugs Market by Drug Class, Distribution Channel & Region - Forecast 2022-2032

Glioblastoma Treatment Drugs Market Outlook (2022-2032)

[333 Pages Report] The glioblastoma treatment drugs market is likely to secure a CAGR of 5.7% during the forecast period. The market is projected to be valued at US$ 723.30 million in 2022 and is expected to be valued at US$ 1,259.13 million by 2032.

The demand for glioblastoma treatment drugs is rising due to increasing geriatric populations and increasing incidence cases in recent years. The adoption of glioblastoma treatment drugs is rising with the increasing number of brain cancer tumour patients.

Moreover, some patients get beneficial clinic trials with the receiving development agents. The biomarkers seem to be more successful in personalized medicine for these patients.

Report Attribute

Details

Glioblastoma Treatment Drugs Market Value (2022)

US$ 723.30 Million

Glioblastoma Treatment Drugs Market Anticipated Value (2032)

US$ 1,259.13 Million

Glioblastoma Treatment Drugs Projected Growth Rate (2032)

5.7%

This tumor is also found in the spinal cord and represents about 15.4% of all primary brain tumors, which increases the demand for glioblastoma treatment drugs. Glioblastoma is difficult to treat because of the number of different types of cells and, thus, various treatment plans combined.

In addition, drugs involved in treating glioblastoma are antineoplastic cytotoxic drugs. There is a significant development in chemotherapy drugs to treat malignant tumors, and each year there are new drugs on the market to overcome the blood-brain barrier.

Moreover, the manufacturers are playing a crucial role in developing and research several drugs for patient treatment that are likely to increase the glioblastoma treatment drugs market share during the forecast period.

Customize this Report

Let us know your requirement to get
100% FREE customization

Essential Drives and Constraint Factors in the Glioblastoma Treatment Drugs Market

Glioblastoma is a complicated disease, and thus the treatment for it involves various approaches combining various treatments, which is the major market driver for the glioblastoma treatment drugs market. Treating such tumours is a challenge, which forces researchers to look for diagnoses and newer chemotherapy drugs.

Changing demography, access to healthcare facilities and financial demands are some factors which are lagging in the further developments of glioblastoma. Gaining a better understanding of this disease and efficient treatment improvise, which is only possible through developments in molecular mechanisms, and clinical trials, leading to more promising and tailored therapeutic approaches.

Regional Insights:

An Eagle Eye on North America Glioblastoma Treatment Drugs Market

Among all the regions, the market is segmented into North America, Latin America, Europe, Asia Pacific and MEA. North America dominates the market by acquiring 36% of the share during the forecast period. One of the main drivers of the regional market growth is government support for the growth of the healthcare industry, as well as high awareness of uncommon conditions, easy access to high-quality medical facilities, and kind reimbursement policies.

Worldwide, there are an estimated 240,000 cases related to brain cancer, and glioblastoma is the most common and lethal disease. Every year in the U.S, there are about 18000 people diagnosed with glioblastoma disease, which has accelerated the glioblastoma treatment drugs market growth in recent years.

Examine European Glioblastoma Treatment Drugs

Europe is likely to hold the second position in the glioblastoma treatment drug market by acquiring 27% of the share during the forecast period. However, in European countries, 25000 cases are reported. Therefore there are prime incidences of this disease, which boost the market share in the region.

Moreover, various treatments are coming forward which can be used alone or in combination with radiotherapy and chemotherapy, but there are chances of reappearance. The UK is a leading country, which highlights the market due to the rising number of chemo patients in the country.

For the long-term survival of glioblastoma, there are newer combination therapies studied, and various clinical trials are to fight against this disease. These are propelling the growth of the glioblastoma treatment drugs market during the forecast period.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Key Trends in Glioblastoma Treatment Drugs 

Recently, Merck & Company's temozolomide drug was preferred and approved by the FDA for patient chemotherapy. However, bevacizumab is a treatment drug which targets VEGF-A in brain therapy patients in their early-stage trial. Bevacizumab is an anti-drug that helps to interfere in the development of blood vessels that grow a tumor. It is one of the most effective drugs approved by the FDA and is widely used to treat glioblastoma.

The U.S. FDA authorized Pfizer's Zirabev, a biosimilar to Avastin, in June 2019 for the treatment of recurring cancers, including colorectal, NSCLC, and glioblastoma. The firm introduced its product in the United States in January 2020.

Additionally, the U.S. FDA approved Samsung's BLA application for its SB8 bevacizumab biosimilar candidate in November 2019, increasing the likelihood that products may be released in the upcoming years.

The U.S. FDA granted fast-track designation to Denovo Biopharma's DB102 (enzastaurin) in July 2020 for the treatment of people who have just received a glioblastoma diagnosis.

Competitive Landscape:

How are Key Players Advancing the Glioblastoma Treatment Drugs Market?

The key players are the main drivers of the market, who have played a crucial role in uplifting the market size in recent years. These players are using several marketing tactics to boost the market by acquiring the lion’s share during the forecast period.

Some of the marketing methodologies adopted by them are mergers, product launches, partnerships, collaborations and others.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Recent Developments in the Glioblastoma Treatment Drugs Market

Some of the developments in glioblastoma are currently under research by prominent manufacturers, as follows:

  • Gene therapy
  • Theraphy on specific tumor - Afatinib, Aldoxorubicin, CBL0137, Val-083
  • Kinase inhibitor
  • Immunotherapy vaccines - Prophage, DCVax-L, Rindopepimut, Gliovac
  • Glioma stem cell targeting
  • Virus
  • MiRNA targeting
  • Others

These are the under-processing development therapies which are likely to be developed by experts and R&D teams in the coming years. The manufacturers are popping out year-on-year with a unique & advanced therapy for glioblastoma treatment.

  • In 2019, Merck company acquired Peloton Therapeutics, which is a bio-therapeutic clinical-stage company. The acquisition helps to treat brain cancer with the strongly developed small molecule to treat hypoxia-inducible factor-2α (HIF-2α). Therefore, these help to treat cancer treatment with more strengthening and are boosting the market size of glioblastoma treatment drugs all around the globe.
  • Lineage Cell Therapeutics and Immunomic Therapeutics came into a licensing deal in April 2021 for the creation of the allogeneic VAC cancer immunotherapy platform, which is used to treat glioblastoma multiform. According to the deal, Lineage received a USD 2 million upfront payment, as well as USD 67 million in commercial milestone payments.

Key Players in the Glioblastoma Treatment Drugs Market are

  • F. Hoffmann-La Roche AG,
  • Merck & Co., Inc.,
  • Sandoz
  • Arbor Pharms LLC.
  • Emcure Pharmaceuticals Ltd.
  • Bristol-Myers Squibb Company
  • Sigma-Tau Pharmaceuticals, Inc.

Report Scope

Report Attribute

Details

Growth Rate

CAGR of 5.7% from 2022 to 2032

Base Year for Estimation

2021

Historical Data

2016-2021

Forecast Period

2022-2032

Quantitative Units

Revenue in US$ million and CAGR from 2022-2032

Report Coverage

Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis

Segments Covered

  • Drug Class
  • Distribution Channel
  • Region

Regions Covered

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East and Africa

Key Countries Profiled

  • U.S
  • Canada
  • Brazil
  • Argentina
  • Germany
  • U.K
  • France
  • Spain
  • Italy
  • Nordics
  • BENELUX
  • Australia & New Zealand
  • China
  • India
  • ASEAN
  • GCC
  • South Africa

Key Companies Profiled

Customization

Available Upon Request

Key Segments:

Based on the Drug Class:

  • Antineoplastic
  • VEGF/VEGFR Inhibitors
  • Alkylating Agents
  • Miscellaneous Antineoplastic

Based on the Distribution Channel:

  • Hospitals
  • Cancer Research Organizations
  • Long Term Care Centers
  • Diagnostic Centers

By Region:

  • North America
  • Latin America
  • Asia Pacific
  • MEA
  • Europe

Frequently Asked Questions

The glioblastoma treatment drugs market is predicted to advance at a CAGR of 5.7% from 2022-to 2032.

North America is anticipated to lead the glioblastoma treatment drugs market during the forecast period.

The glioblastoma treatment drugsmarket is likely to hold a valuation of US$ 1,259.13 million by 2032

The hospital sector is the key driver in the glioblastoma treatment drugs market.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Glioblastoma Treatment Drugs Market Analysis 2017-2021 and Forecast, 2022-2032

    4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021

    4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Glioblastoma Treatment Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Drug Class

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Mn) Analysis By Drug Class , 2017-2021

    5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Drug Class , 2022-2032

        5.3.1. Antineoplastic

        5.3.2. VEGF/VEGFR Inhibitors

        5.3.3. Alkylating Agents

        5.3.4. Miscellaneous Antineoplastic

        5.3.5. Digital Input Output

    5.4. Y-o-Y Growth Trend Analysis By Drug Class , 2017-2021

    5.5. Absolute $ Opportunity Analysis By Drug Class , 2022-2032

6. Global Glioblastoma Treatment Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Mn) Analysis By Distribution Channel, 2017-2021

    6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Distribution Channel, 2022-2032

        6.3.1. Hospitals

        6.3.2. Cancer Research Organizations

        6.3.3. Long Term Care Centers

        6.3.4. Diagnostic Centers

    6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2017-2021

    6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2022-2032

7. Global Glioblastoma Treatment Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Region

    7.1. Introduction

    7.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021

    7.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032

        7.3.1. North America

        7.3.2. Latin America

        7.3.3. Europe

        7.3.4. South Asia

        7.3.5. East Asia

        7.3.6. Oceania

        7.3.7. MEA

    7.4. Market Attractiveness Analysis By Region

8. North America Glioblastoma Treatment Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    8.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    8.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        8.2.1. By Country

            8.2.1.1. U.S.

            8.2.1.2. Canada

        8.2.2. By Drug Class

        8.2.3. By Distribution Channel

    8.3. Market Attractiveness Analysis

        8.3.1. By Country

        8.3.2. By Drug Class

        8.3.3. By Distribution Channel

    8.4. Key Takeaways

9. Latin America Glioblastoma Treatment Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        9.2.1. By Country

            9.2.1.1. Brazil

            9.2.1.2. Mexico

            9.2.1.3. Rest of Latin America

        9.2.2. By Drug Class

        9.2.3. By Distribution Channel

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Drug Class

        9.3.3. By Distribution Channel

    9.4. Key Takeaways

10. Europe Glioblastoma Treatment Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        10.2.1. By Country

            10.2.1.1. Germany

            10.2.1.2. U.K.

            10.2.1.3. France

            10.2.1.4. Spain

            10.2.1.5. Italy

            10.2.1.6. Rest of Europe

        10.2.2. By Drug Class

        10.2.3. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Class

        10.3.3. By Distribution Channel

    10.4. Key Takeaways

11. South Asia Glioblastoma Treatment Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        11.2.1. By Country

            11.2.1.1. India

            11.2.1.2. Malaysia

            11.2.1.3. Singapore

            11.2.1.4. Thailand

            11.2.1.5. Rest of South Asia

        11.2.2. By Drug Class

        11.2.3. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Class

        11.3.3. By Distribution Channel

    11.4. Key Takeaways

12. East Asia Glioblastoma Treatment Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        12.2.1. By Country

            12.2.1.1. China

            12.2.1.2. Japan

            12.2.1.3. South Korea

        12.2.2. By Drug Class

        12.2.3. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Class

        12.3.3. By Distribution Channel

    12.4. Key Takeaways

13. Oceania Glioblastoma Treatment Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        13.2.1. By Country

            13.2.1.1. Australia

            13.2.1.2. New Zealand

        13.2.2. By Drug Class

        13.2.3. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug Class

        13.3.3. By Distribution Channel

    13.4. Key Takeaways

14. MEA Glioblastoma Treatment Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    14.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    14.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        14.2.1. By Country

            14.2.1.1. GCC Countries

            14.2.1.2. South Africa

            14.2.1.3. Israel

            14.2.1.4. Rest of MEA

        14.2.2. By Drug Class

        14.2.3. By Distribution Channel

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Drug Class

        14.3.3. By Distribution Channel

    14.4. Key Takeaways

15. Key Countries Glioblastoma Treatment Drugs Market Analysis

    15.1. U.S.

        15.1.1. Pricing Analysis

        15.1.2. Market Share Analysis, 2021

            15.1.2.1. By Drug Class

            15.1.2.2. By Distribution Channel

    15.2. Canada

        15.2.1. Pricing Analysis

        15.2.2. Market Share Analysis, 2021

            15.2.2.1. By Drug Class

            15.2.2.2. By Distribution Channel

    15.3. Brazil

        15.3.1. Pricing Analysis

        15.3.2. Market Share Analysis, 2021

            15.3.2.1. By Drug Class

            15.3.2.2. By Distribution Channel

    15.4. Mexico

        15.4.1. Pricing Analysis

        15.4.2. Market Share Analysis, 2021

            15.4.2.1. By Drug Class

            15.4.2.2. By Distribution Channel

    15.5. Germany

        15.5.1. Pricing Analysis

        15.5.2. Market Share Analysis, 2021

            15.5.2.1. By Drug Class

            15.5.2.2. By Distribution Channel

    15.6. U.K.

        15.6.1. Pricing Analysis

        15.6.2. Market Share Analysis, 2021

            15.6.2.1. By Drug Class

            15.6.2.2. By Distribution Channel

    15.7. France

        15.7.1. Pricing Analysis

        15.7.2. Market Share Analysis, 2021

            15.7.2.1. By Drug Class

            15.7.2.2. By Distribution Channel

    15.8. Spain

        15.8.1. Pricing Analysis

        15.8.2. Market Share Analysis, 2021

            15.8.2.1. By Drug Class

            15.8.2.2. By Distribution Channel

    15.9. Italy

        15.9.1. Pricing Analysis

        15.9.2. Market Share Analysis, 2021

            15.9.2.1. By Drug Class

            15.9.2.2. By Distribution Channel

    15.10. India

        15.10.1. Pricing Analysis

        15.10.2. Market Share Analysis, 2021

            15.10.2.1. By Drug Class

            15.10.2.2. By Distribution Channel

    15.11. Malaysia

        15.11.1. Pricing Analysis

        15.11.2. Market Share Analysis, 2021

            15.11.2.1. By Drug Class

            15.11.2.2. By Distribution Channel

    15.12. Singapore

        15.12.1. Pricing Analysis

        15.12.2. Market Share Analysis, 2021

            15.12.2.1. By Drug Class

            15.12.2.2. By Distribution Channel

    15.13. Thailand

        15.13.1. Pricing Analysis

        15.13.2. Market Share Analysis, 2021

            15.13.2.1. By Drug Class

            15.13.2.2. By Distribution Channel

    15.14. China

        15.14.1. Pricing Analysis

        15.14.2. Market Share Analysis, 2021

            15.14.2.1. By Drug Class

            15.14.2.2. By Distribution Channel

    15.15. Japan

        15.15.1. Pricing Analysis

        15.15.2. Market Share Analysis, 2021

            15.15.2.1. By Drug Class

            15.15.2.2. By Distribution Channel

    15.16. South Korea

        15.16.1. Pricing Analysis

        15.16.2. Market Share Analysis, 2021

            15.16.2.1. By Drug Class

            15.16.2.2. By Distribution Channel

    15.17. Australia

        15.17.1. Pricing Analysis

        15.17.2. Market Share Analysis, 2021

            15.17.2.1. By Drug Class

            15.17.2.2. By Distribution Channel

    15.18. New Zealand

        15.18.1. Pricing Analysis

        15.18.2. Market Share Analysis, 2021

            15.18.2.1. By Drug Class

            15.18.2.2. By Distribution Channel

    15.19. GCC Countries

        15.19.1. Pricing Analysis

        15.19.2. Market Share Analysis, 2021

            15.19.2.1. By Drug Class

            15.19.2.2. By Distribution Channel

    15.20. South Africa

        15.20.1. Pricing Analysis

        15.20.2. Market Share Analysis, 2021

            15.20.2.1. By Drug Class

            15.20.2.2. By Distribution Channel

    15.21. Israel

        15.21.1. Pricing Analysis

        15.21.2. Market Share Analysis, 2021

            15.21.2.1. By Drug Class

            15.21.2.2. By Distribution Channel

16. Market Structure Analysis

    16.1. Competition Dashboard

    16.2. Competition Benchmarking

    16.3. Market Share Analysis of Top Players

        16.3.1. By Regional

        16.3.2. By Drug Class

        16.3.3. By Distribution Channel

17. Competition Analysis

    17.1. Competition Deep Dive

        17.1.1. F. Hoffmann-La Roche AG

            17.1.1.1. Overview

            17.1.1.2. Product Portfolio

            17.1.1.3. Profitability by Market Segments

            17.1.1.4. Sales Footprint

            17.1.1.5. Strategy Overview

                17.1.1.5.1. Marketing Strategy

        17.1.2. Merck & Co., Inc.

            17.1.2.1. Overview

            17.1.2.2. Product Portfolio

            17.1.2.3. Profitability by Market Segments

            17.1.2.4. Sales Footprint

            17.1.2.5. Strategy Overview

                17.1.2.5.1. Marketing Strategy

        17.1.3. Sandoz

            17.1.3.1. Overview

            17.1.3.2. Product Portfolio

            17.1.3.3. Profitability by Market Segments

            17.1.3.4. Sales Footprint

            17.1.3.5. Strategy Overview

                17.1.3.5.1. Marketing Strategy

        17.1.4. Arbor Pharms LLC.

            17.1.4.1. Overview

            17.1.4.2. Product Portfolio

            17.1.4.3. Profitability by Market Segments

            17.1.4.4. Sales Footprint

            17.1.4.5. Strategy Overview

                17.1.4.5.1. Marketing Strategy

        17.1.5. Emcure Pharmaceuticals Ltd.

            17.1.5.1. Overview

            17.1.5.2. Product Portfolio

            17.1.5.3. Profitability by Market Segments

            17.1.5.4. Sales Footprint

            17.1.5.5. Strategy Overview

                17.1.5.5.1. Marketing Strategy

        17.1.6. Bristol-Myers Squibb Company

            17.1.6.1. Overview

            17.1.6.2. Product Portfolio

            17.1.6.3. Profitability by Market Segments

            17.1.6.4. Sales Footprint

            17.1.6.5. Strategy Overview

                17.1.6.5.1. Marketing Strategy

        17.1.7. Sigma-Tau Pharmaceuticals, Inc.

            17.1.7.1. Overview

            17.1.7.2. Product Portfolio

            17.1.7.3. Profitability by Market Segments

            17.1.7.4. Sales Footprint

            17.1.7.5. Strategy Overview

                17.1.7.5.1. Marketing Strategy

        17.1.8. Cipla Ltd.

            17.1.8.1. Overview

            17.1.8.2. Product Portfolio

            17.1.8.3. Profitability by Market Segments

            17.1.8.4. Sales Footprint

            17.1.8.5. Strategy Overview

                17.1.8.5.1. Marketing Strategy

        17.1.9. Hikma Pharmaceuticals PLC

            17.1.9.1. Overview

            17.1.9.2. Product Portfolio

            17.1.9.3. Profitability by Market Segments

            17.1.9.4. Sales Footprint

            17.1.9.5. Strategy Overview

                17.1.9.5.1. Marketing Strategy

        17.1.10. Teva Pharmaceutical Industries Ltd,

            17.1.10.1. Overview

            17.1.10.2. Product Portfolio

            17.1.10.3. Profitability by Market Segments

            17.1.10.4. Sales Footprint

            17.1.10.5. Strategy Overview

                17.1.10.5.1. Marketing Strategy

18. Assumptions & Acronyms Used

19. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 1: Global Glioblastoma Treatment Drugs Market Value (US$ Mn) Forecast by Region, 2017-2032

Table 2: Global Glioblastoma Treatment Drugs Market Value (US$ Mn) Forecast by Drug Class , 2017-2032

Table 3: Global Glioblastoma Treatment Drugs Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032

Table 4: North America Glioblastoma Treatment Drugs Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 5: North America Glioblastoma Treatment Drugs Market Value (US$ Mn) Forecast by Drug Class , 2017-2032

Table 6: North America Glioblastoma Treatment Drugs Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032

Table 7: Latin America Glioblastoma Treatment Drugs Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 8: Latin America Glioblastoma Treatment Drugs Market Value (US$ Mn) Forecast by Drug Class , 2017-2032

Table 9: Latin America Glioblastoma Treatment Drugs Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032

Table 10: Europe Glioblastoma Treatment Drugs Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 11: Europe Glioblastoma Treatment Drugs Market Value (US$ Mn) Forecast by Drug Class , 2017-2032

Table 12: Europe Glioblastoma Treatment Drugs Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032

Table 13: South Asia Glioblastoma Treatment Drugs Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 14: South Asia Glioblastoma Treatment Drugs Market Value (US$ Mn) Forecast by Drug Class , 2017-2032

Table 15: South Asia Glioblastoma Treatment Drugs Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032

Table 16: East Asia Glioblastoma Treatment Drugs Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 17: East Asia Glioblastoma Treatment Drugs Market Value (US$ Mn) Forecast by Drug Class , 2017-2032

Table 18: East Asia Glioblastoma Treatment Drugs Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032

Table 19: Oceania Glioblastoma Treatment Drugs Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 20: Oceania Glioblastoma Treatment Drugs Market Value (US$ Mn) Forecast by Drug Class , 2017-2032

Table 21: Oceania Glioblastoma Treatment Drugs Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032

Table 22: MEA Glioblastoma Treatment Drugs Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 23: MEA Glioblastoma Treatment Drugs Market Value (US$ Mn) Forecast by Drug Class , 2017-2032

Table 24: MEA Glioblastoma Treatment Drugs Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 1: Global Glioblastoma Treatment Drugs Market Value (US$ Mn) by Drug Class , 2022-2032

Figure 2: Global Glioblastoma Treatment Drugs Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 3: Global Glioblastoma Treatment Drugs Market Value (US$ Mn) by Region, 2022-2032

Figure 4: Global Glioblastoma Treatment Drugs Market Value (US$ Mn) Analysis by Region, 2017-2032

Figure 5: Global Glioblastoma Treatment Drugs Market Value Share (%) and BPS Analysis by Region, 2022-2032

Figure 6: Global Glioblastoma Treatment Drugs Market Y-o-Y Growth (%) Projections by Region, 2022-2032

Figure 7: Global Glioblastoma Treatment Drugs Market Value (US$ Mn) Analysis by Drug Class , 2017-2032

Figure 8: Global Glioblastoma Treatment Drugs Market Value Share (%) and BPS Analysis by Drug Class , 2022-2032

Figure 9: Global Glioblastoma Treatment Drugs Market Y-o-Y Growth (%) Projections by Drug Class , 2022-2032

Figure 10: Global Glioblastoma Treatment Drugs Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032

Figure 11: Global Glioblastoma Treatment Drugs Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 12: Global Glioblastoma Treatment Drugs Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 13: Global Glioblastoma Treatment Drugs Market Attractiveness by Drug Class , 2022-2032

Figure 14: Global Glioblastoma Treatment Drugs Market Attractiveness by Distribution Channel, 2022-2032

Figure 15: Global Glioblastoma Treatment Drugs Market Attractiveness by Region, 2022-2032

Figure 16: North America Glioblastoma Treatment Drugs Market Value (US$ Mn) by Drug Class , 2022-2032

Figure 17: North America Glioblastoma Treatment Drugs Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 18: North America Glioblastoma Treatment Drugs Market Value (US$ Mn) by Country, 2022-2032

Figure 19: North America Glioblastoma Treatment Drugs Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 20: North America Glioblastoma Treatment Drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 21: North America Glioblastoma Treatment Drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 22: North America Glioblastoma Treatment Drugs Market Value (US$ Mn) Analysis by Drug Class , 2017-2032

Figure 23: North America Glioblastoma Treatment Drugs Market Value Share (%) and BPS Analysis by Drug Class , 2022-2032

Figure 24: North America Glioblastoma Treatment Drugs Market Y-o-Y Growth (%) Projections by Drug Class , 2022-2032

Figure 25: North America Glioblastoma Treatment Drugs Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032

Figure 26: North America Glioblastoma Treatment Drugs Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 27: North America Glioblastoma Treatment Drugs Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 28: North America Glioblastoma Treatment Drugs Market Attractiveness by Drug Class , 2022-2032

Figure 29: North America Glioblastoma Treatment Drugs Market Attractiveness by Distribution Channel, 2022-2032

Figure 30: North America Glioblastoma Treatment Drugs Market Attractiveness by Country, 2022-2032

Figure 31: Latin America Glioblastoma Treatment Drugs Market Value (US$ Mn) by Drug Class , 2022-2032

Figure 32: Latin America Glioblastoma Treatment Drugs Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 33: Latin America Glioblastoma Treatment Drugs Market Value (US$ Mn) by Country, 2022-2032

Figure 34: Latin America Glioblastoma Treatment Drugs Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 35: Latin America Glioblastoma Treatment Drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 36: Latin America Glioblastoma Treatment Drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 37: Latin America Glioblastoma Treatment Drugs Market Value (US$ Mn) Analysis by Drug Class , 2017-2032

Figure 38: Latin America Glioblastoma Treatment Drugs Market Value Share (%) and BPS Analysis by Drug Class , 2022-2032

Figure 39: Latin America Glioblastoma Treatment Drugs Market Y-o-Y Growth (%) Projections by Drug Class , 2022-2032

Figure 40: Latin America Glioblastoma Treatment Drugs Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032

Figure 41: Latin America Glioblastoma Treatment Drugs Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 42: Latin America Glioblastoma Treatment Drugs Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 43: Latin America Glioblastoma Treatment Drugs Market Attractiveness by Drug Class , 2022-2032

Figure 44: Latin America Glioblastoma Treatment Drugs Market Attractiveness by Distribution Channel, 2022-2032

Figure 45: Latin America Glioblastoma Treatment Drugs Market Attractiveness by Country, 2022-2032

Figure 46: Europe Glioblastoma Treatment Drugs Market Value (US$ Mn) by Drug Class , 2022-2032

Figure 47: Europe Glioblastoma Treatment Drugs Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 48: Europe Glioblastoma Treatment Drugs Market Value (US$ Mn) by Country, 2022-2032

Figure 49: Europe Glioblastoma Treatment Drugs Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 50: Europe Glioblastoma Treatment Drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 51: Europe Glioblastoma Treatment Drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 52: Europe Glioblastoma Treatment Drugs Market Value (US$ Mn) Analysis by Drug Class , 2017-2032

Figure 53: Europe Glioblastoma Treatment Drugs Market Value Share (%) and BPS Analysis by Drug Class , 2022-2032

Figure 54: Europe Glioblastoma Treatment Drugs Market Y-o-Y Growth (%) Projections by Drug Class , 2022-2032

Figure 55: Europe Glioblastoma Treatment Drugs Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032

Figure 56: Europe Glioblastoma Treatment Drugs Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 57: Europe Glioblastoma Treatment Drugs Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 58: Europe Glioblastoma Treatment Drugs Market Attractiveness by Drug Class , 2022-2032

Figure 59: Europe Glioblastoma Treatment Drugs Market Attractiveness by Distribution Channel, 2022-2032

Figure 60: Europe Glioblastoma Treatment Drugs Market Attractiveness by Country, 2022-2032

Figure 61: South Asia Glioblastoma Treatment Drugs Market Value (US$ Mn) by Drug Class , 2022-2032

Figure 62: South Asia Glioblastoma Treatment Drugs Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 63: South Asia Glioblastoma Treatment Drugs Market Value (US$ Mn) by Country, 2022-2032

Figure 64: South Asia Glioblastoma Treatment Drugs Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 65: South Asia Glioblastoma Treatment Drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 66: South Asia Glioblastoma Treatment Drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 67: South Asia Glioblastoma Treatment Drugs Market Value (US$ Mn) Analysis by Drug Class , 2017-2032

Figure 68: South Asia Glioblastoma Treatment Drugs Market Value Share (%) and BPS Analysis by Drug Class , 2022-2032

Figure 69: South Asia Glioblastoma Treatment Drugs Market Y-o-Y Growth (%) Projections by Drug Class , 2022-2032

Figure 70: South Asia Glioblastoma Treatment Drugs Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032

Figure 71: South Asia Glioblastoma Treatment Drugs Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 72: South Asia Glioblastoma Treatment Drugs Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 73: South Asia Glioblastoma Treatment Drugs Market Attractiveness by Drug Class , 2022-2032

Figure 74: South Asia Glioblastoma Treatment Drugs Market Attractiveness by Distribution Channel, 2022-2032

Figure 75: South Asia Glioblastoma Treatment Drugs Market Attractiveness by Country, 2022-2032

Figure 76: East Asia Glioblastoma Treatment Drugs Market Value (US$ Mn) by Drug Class , 2022-2032

Figure 77: East Asia Glioblastoma Treatment Drugs Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 78: East Asia Glioblastoma Treatment Drugs Market Value (US$ Mn) by Country, 2022-2032

Figure 79: East Asia Glioblastoma Treatment Drugs Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 80: East Asia Glioblastoma Treatment Drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 81: East Asia Glioblastoma Treatment Drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 82: East Asia Glioblastoma Treatment Drugs Market Value (US$ Mn) Analysis by Drug Class , 2017-2032

Figure 83: East Asia Glioblastoma Treatment Drugs Market Value Share (%) and BPS Analysis by Drug Class , 2022-2032

Figure 84: East Asia Glioblastoma Treatment Drugs Market Y-o-Y Growth (%) Projections by Drug Class , 2022-2032

Figure 85: East Asia Glioblastoma Treatment Drugs Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032

Figure 86: East Asia Glioblastoma Treatment Drugs Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 87: East Asia Glioblastoma Treatment Drugs Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 88: East Asia Glioblastoma Treatment Drugs Market Attractiveness by Drug Class , 2022-2032

Figure 89: East Asia Glioblastoma Treatment Drugs Market Attractiveness by Distribution Channel, 2022-2032

Figure 90: East Asia Glioblastoma Treatment Drugs Market Attractiveness by Country, 2022-2032

Figure 91: Oceania Glioblastoma Treatment Drugs Market Value (US$ Mn) by Drug Class , 2022-2032

Figure 92: Oceania Glioblastoma Treatment Drugs Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 93: Oceania Glioblastoma Treatment Drugs Market Value (US$ Mn) by Country, 2022-2032

Figure 94: Oceania Glioblastoma Treatment Drugs Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 95: Oceania Glioblastoma Treatment Drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 96: Oceania Glioblastoma Treatment Drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 97: Oceania Glioblastoma Treatment Drugs Market Value (US$ Mn) Analysis by Drug Class , 2017-2032

Figure 98: Oceania Glioblastoma Treatment Drugs Market Value Share (%) and BPS Analysis by Drug Class , 2022-2032

Figure 99: Oceania Glioblastoma Treatment Drugs Market Y-o-Y Growth (%) Projections by Drug Class , 2022-2032

Figure 100: Oceania Glioblastoma Treatment Drugs Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032

Figure 101: Oceania Glioblastoma Treatment Drugs Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 102: Oceania Glioblastoma Treatment Drugs Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 103: Oceania Glioblastoma Treatment Drugs Market Attractiveness by Drug Class , 2022-2032

Figure 104: Oceania Glioblastoma Treatment Drugs Market Attractiveness by Distribution Channel, 2022-2032

Figure 105: Oceania Glioblastoma Treatment Drugs Market Attractiveness by Country, 2022-2032

Figure 106: MEA Glioblastoma Treatment Drugs Market Value (US$ Mn) by Drug Class , 2022-2032

Figure 107: MEA Glioblastoma Treatment Drugs Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 108: MEA Glioblastoma Treatment Drugs Market Value (US$ Mn) by Country, 2022-2032

Figure 109: MEA Glioblastoma Treatment Drugs Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 110: MEA Glioblastoma Treatment Drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 111: MEA Glioblastoma Treatment Drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 112: MEA Glioblastoma Treatment Drugs Market Value (US$ Mn) Analysis by Drug Class , 2017-2032

Figure 113: MEA Glioblastoma Treatment Drugs Market Value Share (%) and BPS Analysis by Drug Class , 2022-2032

Figure 114: MEA Glioblastoma Treatment Drugs Market Y-o-Y Growth (%) Projections by Drug Class , 2022-2032

Figure 115: MEA Glioblastoma Treatment Drugs Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032

Figure 116: MEA Glioblastoma Treatment Drugs Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 117: MEA Glioblastoma Treatment Drugs Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 118: MEA Glioblastoma Treatment Drugs Market Attractiveness by Drug Class , 2022-2032

Figure 119: MEA Glioblastoma Treatment Drugs Market Attractiveness by Distribution Channel, 2022-2032

Figure 120: MEA Glioblastoma Treatment Drugs Market Attractiveness by Country, 2022-2032

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Antimetabolite Drugs Market

Published : June 2020

Healthcare

Retinal Drugs And Biologics Market

Published : May 2017

Healthcare

Retinoblastoma Treatment Market

Published : January 1970

Google translate

Glioblastoma Treatment Drugs Market